Furthermore, patients with low MYH9 expression levels in their ccRCC had a more significant improvement in PFS after receiving sunitinib when compared with those in patients with high MYH9 expression (Fig. 8e). Here, MYH9 is linked to nonpapillary renal cell carcinoma.